Please login to the form below

Not currently logged in
Email:
Password:

Eucomed commits to value-based innovation

Eucomed, the European medical technology body, has launched its five-year strategy, which includes a commitment to value-based innovation

Eucomed, the European medical technology body, has launched its five-year strategy, which includes a commitment to value-based innovation.

The association presented its 'Contract for a Healthy Future' report at the MedTech Forum in Brussels, Belgium, describing the role the medical technology industry must take to ensure healthcare across Europe has a sustainable future.

The strategy includes plans to deliver and demonstrate cost-efficiency and health outcome needs of payers and policymakers.

Guy Lebeau, chairman of Eucomed, said: "The future will demand a different kind of innovative thinking from all stakeholders in our economies.

"We will take the first step and deliver value-based innovations that deliver a demonstrable positive return on investment in healthy life years for citizens."

The strategy also outlines Eucomed's demands to healthcare stakeholders across Europe, requesting that policymakers build better cost models and end silo-based budgeting. Payers are asked to achieve health productivity and efficiency by prioritising value not price.

This supports a separate report published by the Economist Intelligence Unit (EIU) that says the medical technology industry in Europe must support healthcare in the region by collecting, developing and sharing evidence-based cases of technologies that demonstrate the real value in innovation.

Download both reports from Reforming Healthcare in Europe.

12th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics